To read the full story, subscribe or sign in.

Duchembio files for IPO to grow radiopharma business

Nov. 12, 2024

Radiopharmaceutical biotech and contract development and organization firm Duchembio Co. Ltd. filed a securities report to South Korea’s Financial Services Commission Nov. 11, kickstarting the IPO process to list on the Korea Exchange.

BioWorld Asia Financings Aging Cancer Neurology/psychiatric Small molecule IPO Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 16, 2025.

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...

PHD inhibitors reported in Akebia Therapeutics patent

BioWorld Science

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.

Woman in military clothing talking with psychologist

FDA wants more data for Otsuka’s sNDA in PTSD

BioWorld

The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with...